Class Action Targets Drug Makers Who Sold NDMA-Contaminated Valsartan Drugs
August 20, 2018
NEW YORK — Two New York citizens have filed a purported class action against two drug makers, alleging they negligently sold valsartan-containing drugs that became contaminated with a known carcinogen during the manufacturing process.
The complaint, filed on Aug. 16 in the U.S. District Court for the Southern District of New York, says the drug makers knew or should have known that the valsartan-containing generic medications were contaminated with NDMA, which can cause liver cancer.
Plaintiffs Elizabeth and John Duffy filed the action on behalf of a purported class of consumers who purchased valsartan-containing drugs from defendants Solco Healthcare U.S. …
- Burson & Fisher